| Title |
Regenerative approaches for the treatment of early OA
|
|---|---|
| Published in |
Knee Surgery, Sports Traumatology, Arthroscopy, April 2016
|
| DOI | 10.1007/s00167-016-4125-y |
| Pubmed ID | |
| Authors |
L. de Girolamo, E. Kon, G. Filardo, A. G. Marmotti, F. Soler, G. M. Peretti, F. Vannini, H. Madry, S. Chubinskaya |
| Abstract |
The diagnosis and the prompt treatment of early osteoarthritis (OA) represent vital steps for delaying the onset and progression of fully blown OA, which is the most common form of arthritis, involving more than 10 % of the world's population older than 60 years of age. Nonsurgical treatments such as physiotherapy, anti-inflammatory medications, and other disease-modifying drugs all have modest and short-lasting effect. In this context, the biological approaches have recently gained more and more attention. Growth factors, blood derivatives, such as platelet concentrates, and mesenchymal adult stem cells, either expanded or freshly isolated, are advocated amongst the most promising tool for the treatment of OA, especially in the early phases. Primarily targeted towards focal cartilage defects, these biological agents have indeed recently showed promising results to relieve pain and reduce inflammation in patients with more advanced OA as well, with the final aim to halt the progression of the disease and the need for joint replacement. However, despite of a number of satisfactory in vitro and pre-clinical studies, the evidences are still limited to support their clinical efficacy in OA setting. Level of evidence V. |
Mendeley readers
The data shown below were compiled from readership statistics for 116 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 116 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 17 | 15% |
| Student > Master | 14 | 12% |
| Student > Doctoral Student | 13 | 11% |
| Researcher | 11 | 9% |
| Other | 8 | 7% |
| Other | 23 | 20% |
| Unknown | 30 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 54 | 47% |
| Biochemistry, Genetics and Molecular Biology | 6 | 5% |
| Neuroscience | 3 | 3% |
| Engineering | 3 | 3% |
| Veterinary Science and Veterinary Medicine | 3 | 3% |
| Other | 11 | 9% |
| Unknown | 36 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 November 2017.
All research outputs
#7,280,433
of 22,971,207 outputs
Outputs from Knee Surgery, Sports Traumatology, Arthroscopy
#969
of 2,669 outputs
Outputs of similar age
#103,152
of 299,419 outputs
Outputs of similar age from Knee Surgery, Sports Traumatology, Arthroscopy
#18
of 48 outputs
Altmetric has tracked 22,971,207 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 2,669 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 299,419 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.
We're also able to compare this research output to 48 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.